RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018. jaimeuss_admin 17 בSeptember 2018 Research 0 Comments Continue Reading
RedHill Biopharma Ltd.: The Strategic Expansion and Clinical Progress are in line with the Company’s plans. Stock Target Price Unchanged. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading
Energix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading